A5045925835- Glioma Diagnosis and Treatment
- MicroRNA in disease regulation
- Brain Metastases and Treatment
- Cancer, Hypoxia, and Metabolism
- Cancer-related molecular mechanisms research
- RNA modifications and cancer
- Cancer Genomics and Diagnostics
- Meningioma and schwannoma management
- Cancer Treatment and Pharmacology
- Radiomics and Machine Learning in Medical Imaging
- Histone Deacetylase Inhibitors Research
- Single-cell and spatial transcriptomics
- Neuroblastoma Research and Treatments
- Cancer Cells and Metastasis
- Virus-based gene therapy research
- Epigenetics and DNA Methylation
- RNA Research and Splicing
- Wnt/β-catenin signaling in development and cancer
- Genomic variations and chromosomal abnormalities
- Angiogenesis and VEGF in Cancer
- Genomics and Chromatin Dynamics
- Lung Cancer Treatments and Mutations
- Cell Image Analysis Techniques
- Gene expression and cancer classification
- Nuclear Receptors and Signaling
New York Hospital Queens
2015-2025
NewYork–Presbyterian Hospital
2015-2025
Cornell University
2016-2025
Weill Cornell Medicine
2017-2025
Presbyterian Hospital
2015-2024
Italian Institute of Technology
2024
National Institute of Neurological Disorders and Stroke
2005-2023
National Cancer Institute
2006-2023
Cancer Institute (WIA)
2005-2023
Georgetown University
2023
To evaluate single-agent activity of bevacizumab in patients with recurrent glioblastoma.Patients glioblastoma were treated 10 mg/kg every 2 weeks. After tumor progression, immediately combination irinotecan 340 mg/m(2) or 125 weeks, depending on use enzyme-inducing antiepileptic drugs. Complete patient evaluations repeated 4 weeks.Forty-eight heavily pretreated accrued to this study. Thromboembolic events (12.5%), hypertension hypophosphatemia (6%), and thrombocytopenia (6%) the most common...
microRNAs are noncoding RNAs inhibiting expression of numerous target genes, and a few have been shown to act as oncogenes or tumor suppressors. We show that microRNA-7 (miR-7) is potential suppressor in glioblastoma targeting critical cancer pathways. miR-7 potently suppressed epidermal growth factor receptor expression, furthermore it independently inhibited the Akt pathway via upstream regulators. was down-regulated versus surrounding brain, with mechanism involving impaired processing....
Background: The spread of systemic cancer to the brain is a common complication for patients. Conventional radiotherapy offers modest palliation, and surgery helpful only patient with single metastasis in an accessible location. Stereotactic radiosurgery, technique that permits precise delivery high dose radiation small in-tracranial target while sparing surrounding normal brain, has been used as alternative treatment metastases. Purpose: Our medical center's 7-year experience radiosurgery...
The Notch family of proteins plays an integral role in determining cell fates, such as proliferation, differentiation, and apoptosis. We show that Notch-1 its ligands, Delta-like-1 Jagged-1, are overexpressed many glioma lines primary human gliomas. Immunohistochemistry a tissue array shows the presence nucleus intracellular domain, indicating activation situ. Down-regulation Notch-1, Delta-like-1, or Jagged-1 by RNA interference induces apoptosis inhibits proliferation multiple lines. In...
This phase III open-label study compared the efficacy and safety of enzastaurin versus lomustine in patients with recurrent glioblastoma (WHO grade 4).Patients were randomly assigned 2:1 to receive 6-week cycles 500 mg/d (1,125-mg loading dose, day 1) or (100 130 mg/m(2), 1). Assuming a 45% improvement progression-free survival (PFS), 397 required provide 80% power achieve statistical significance at one-sided level .025.Enrollment was terminated 266 (enzastaurin, n = 174; lomustine, 92)...
Concern has arisen that the use of hand-held cellular telephones might cause brain tumors. If such a risk does exist, matter would be considerable public health importance, given rapid increase worldwide in these devices.
PURPOSE: Little progress has been made in the treatment of adult high-grade gliomas over last two decades, thus necessitating a search for novel therapeutic strategies. Malignant are vascular or angiogenic tumors, which leads to supposition that angiogenesis inhibition may represent potentially promising strategy these tumors. We present results phase II trial thalidomide, putative inhibitor angiogenesis, adults with previously irradiated, recurrent gliomas. PATIENTS AND METHODS: Patients...
Phase I: To determine the maximum tolerated doses, toxicities, and pharmacokinetics of imatinib mesylate (Gleevec) in patients with malignant gliomas taking enzyme-inducing antiepileptic drugs (EIAED) or not EIAED. II: therapeutic efficacy imatinib.Phase I component used an interpatient dose escalation scheme. End points phase II were 6-month progression-free survival response.Fifty enrolled (27 EIAED 23 non-EIAED). The for non-EIAED was 800 mg/d. Dose-limiting toxicities neutropenia, rash,...
Finding better therapies for the treatment of brain tumors is hampered by lack consistently obtained molecular data in a large sample set and ability to integrate biomedical from disparate sources enabling translation bench bedside. Hence, critical factor advancement research clinical ease with which can be integrated, redistributed, analyzed both within across functional domains. Novel informatics infrastructure tools are essential developing individualized patient based on specific genomic...
The North American Brain Tumor Consortium (NABTC) uses 6-month progression-free survival (6moPFS) as the efficacy end point of therapy trials for adult patients with recurrent high-grade gliomas. In this study, we investigated whether progression status at 6 months predicts from that time, implying potential prolonged if could be delayed. We also evaluated earlier time points to determine assessment alters strength prediction. Data were 596 patient enrollments (159 grade III gliomas and 437...
The prognosis of patients with glioblastoma (GBM) remains dismal, a median survival approximately 15 months. Current preclinical GBM models are limited by the lack "normal" human microenvironment and inability many tumor cell lines to accurately reproduce biology. To address these limitations, we have established model system whereby can retro-engineer patient-specific GBMs using patient-derived glioma stem cells (GSCs) embryonic (hESC)-derived cerebral organoids. Our organoid (GLICO) shows...
Abstract Activation of the epidermal growth factor receptor (EGFR) in glioblastoma (GBM) occurs through mutations or deletions extracellular (EC) domain. Unlike lung cancers with EGFR kinase domain (KD) mutations, GBMs respond poorly to inhibitor erlotinib. Using RNAi, we show that GBM cells carrying EC display addiction. In contrast KD mutants found cancer, glioma-specific are inhibited by inhibitors target active conformation (e.g., erlotinib). Inhibitors bind inactive conformation,...
Despite initial treatment with surgical resection, radiotherapy, and chemotherapy, glioblastoma multiforme (GBM) virtually always recurs. Surgery is sometimes recommended to treat recurrence. In this study, we sought devise a preoperative scale that predicts survival after surgery for recurrent multiforme.The clinical radiographic data of 34 patients who underwent re-operation GBM tumors were analyzed using Kaplan-Meier analysis Cox proportional hazards regression modeling. The factors...
A deletion variant of epidermal growth factor receptor (EGFRvIII) is a known driver mutation in subset primary and secondary glioblastoma multiforme. Adoptive transfer genetically modified chimeric antigen (CAR) lymphocytes has demonstrated efficacy hematologic malignancies but still early development for solid cancers. The surface expression the truncated extracellular ligand domain created by EGFRvIII makes it an attractive target CAR-based cancer treatment. Patients with recurrent...
No curative treatment exists for glioblastoma, with median survival times of less than 2 years from diagnosis. As an approach to develop immune-based therapies we sought target antigens expressed in glioma stem cells (GSCs). GSCs have multiple properties that make them significantly more representative tumors established cell lines. Epidermal growth factor receptor variant III (EGFRvIII) is the result a novel tumor-specific gene rearrangement produces unique protein approximately 30%...
The Rembrandt brain cancer dataset includes 671 patients collected from 14 contributing institutions 2004-2006. It is accessible for conducting clinical translational research using the open access Georgetown Database of Cancer (G-DOC) platform. In addition, raw and processed genomics transcriptomics data have also been made available via public NCBI GEO repository as a super series GSE108476. Such combined datasets would provide researchers with unique opportunity to conduct integrative...
Significance Human PSC-derived iBMECs have been generated to study disease mechanisms and drug development for neurological disorders. However, their full transcriptomic characterization is unclear, which could result in inaccurate physiological studies of treatments with ineffective clinical outcomes. Utilizing a comprehensive metaanalysis validated by studies, we find that many current protocols used generate produce homogenous epithelial cell population. Overexpression ETS transcription...